FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2954184793> ?p ?o ?g. }

• W2954184793 endingPage "2033" @default.
• W2954184793 startingPage "2025" @default.
• W2954184793 abstract "Objective: To evaluate whether initiation of etanercept therapy among patients with rheumatoid arthritis (RA) impacts use of co-therapy with methotrexate or prednisone, and to describe etanercept dosing dynamics compared to product monograph in the Canadian real-world setting.Methods: A retrospective cohort study was conducted using claims-level data from IQVIA Private Drug Plan database, Ontario Public Drug Plan database and Régie de l’assurance maladie du Québec database. Bio-naïve RA patients initiating etanercept between July 2014 and June 2015 were identified and their claims for methotrexate or prednisone were analyzed. Utilization of methotrexate or prednisone was calculated as average weekly dose in milligrams, and compared in the 6 months pre-initiation versus 12 months post-initiation of etanercept. Weekly etanercept dosing of each patient was calculated and analyzed to determine whether patients had at least 20% higher or lower average dose than monograph recommended dose (50 mg/week), and were then flagged as above-monograph or below-monograph, respectively.Results: A total of 2876 patients with RA (66% female, 76% aged 18–65) were included; 62% (n = 1,140) used methotrexate and 27% used prednisone (n = 498) both pre- and post-initiation of etanercept. In methotrexate patients, the average weekly dose dispensed was 25.4 mg in the 6 months pre-etanercept, and 25.0 mg in the 12 months post-etanercept initiation (p = .5282). In prednisone patients, the average weekly dose dispensed reduced from 122.6 mg pre-etanercept to 107.1 mg post-etanercept initiation (p = .2173). Among patients who were already on methotrexate or prednisone, after initiating on etanercept 16% (n = 213) and 34% (n = 254) of patients stopped methotrexate and prednisone, respectively. When compared to the recommended dose, 12% (n = 168) of patients were below-monograph and 7.1% of patients were above-monograph during their first year of etanercept therapy. Average etanercept dosing was consistently lower than product monograph during the follow-up year.Conclusions: Patients had a modest but not statistically significant decrease in prescribed doses of co-therapy with methotrexate and prednisone when etanercept was added to patients’ therapy. In addition, 12–14% of patients stopped their co-therapy with methotrexate or prednisone. Further study is needed to understand the impact on patient outcomes and safety." @default.
• W2954184793 created "2019-07-12" @default.
• W2954184793 creator A5002884556 @default.
• W2954184793 creator A5009475149 @default.
• W2954184793 creator A5009769959 @default.
• W2954184793 creator A5019480231 @default.
• W2954184793 creator A5032283613 @default.
• W2954184793 creator A5033721412 @default.
• W2954184793 creator A5054267527 @default.
• W2954184793 creator A5056879469 @default.
• W2954184793 date "2019-07-10" @default.
• W2954184793 modified "2023-09-26" @default.
• W2954184793 title "Real-world utilization of methotrexate or prednisone co-therapy with etanercept among Canadian patients with rheumatoid arthritis: a retrospective cohort study" @default.
• W2954184793 cites W118352842 @default.
• W2954184793 cites W1539312716 @default.
• W2954184793 cites W1785296647 @default.
• W2954184793 cites W1808657932 @default.
• W2954184793 cites W1980525146 @default.
• W2954184793 cites W2006179674 @default.
• W2954184793 cites W2019460882 @default.
• W2954184793 cites W2022849682 @default.
• W2954184793 cites W2035524760 @default.
• W2954184793 cites W2055280685 @default.
• W2954184793 cites W2070055998 @default.
• W2954184793 cites W2087204357 @default.
• W2954184793 cites W2105367456 @default.
• W2954184793 cites W2109445459 @default.
• W2954184793 cites W2114909821 @default.
• W2954184793 cites W2115068885 @default.
• W2954184793 cites W2124007067 @default.
• W2954184793 cites W2131563771 @default.
• W2954184793 cites W2141953337 @default.
• W2954184793 cites W2154986972 @default.
• W2954184793 cites W2165933132 @default.
• W2954184793 cites W2314052274 @default.
• W2954184793 cites W2334121790 @default.
• W2954184793 cites W2546668519 @default.
• W2954184793 cites W2740030721 @default.
• W2954184793 cites W2803973097 @default.
• W2954184793 cites W2804981378 @default.
• W2954184793 cites W4210768724 @default.
• W2954184793 doi "https://doi.org/10.1080/03007995.2019.1636543" @default.
• W2954184793 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31237785" @default.
• W2954184793 hasPublicationYear "2019" @default.
• W2954184793 type Work @default.
• W2954184793 sameAs 2954184793 @default.
• W2954184793 citedByCount "2" @default.
• W2954184793 countsByYear W29541847932022 @default.
• W2954184793 crossrefType "journal-article" @default.
• W2954184793 hasAuthorship W2954184793A5002884556 @default.
• W2954184793 hasAuthorship W2954184793A5009475149 @default.
• W2954184793 hasAuthorship W2954184793A5009769959 @default.
• W2954184793 hasAuthorship W2954184793A5019480231 @default.
• W2954184793 hasAuthorship W2954184793A5032283613 @default.
• W2954184793 hasAuthorship W2954184793A5033721412 @default.
• W2954184793 hasAuthorship W2954184793A5054267527 @default.
• W2954184793 hasAuthorship W2954184793A5056879469 @default.
• W2954184793 hasConcept C126322002 @default.
• W2954184793 hasConcept C167135981 @default.
• W2954184793 hasConcept C2777226972 @default.
• W2954184793 hasConcept C2777288759 @default.
• W2954184793 hasConcept C2777575956 @default.
• W2954184793 hasConcept C2778720950 @default.
• W2954184793 hasConcept C2781059491 @default.
• W2954184793 hasConcept C71924100 @default.
• W2954184793 hasConcept C72563966 @default.
• W2954184793 hasConceptScore W2954184793C126322002 @default.
• W2954184793 hasConceptScore W2954184793C167135981 @default.
• W2954184793 hasConceptScore W2954184793C2777226972 @default.
• W2954184793 hasConceptScore W2954184793C2777288759 @default.
• W2954184793 hasConceptScore W2954184793C2777575956 @default.
• W2954184793 hasConceptScore W2954184793C2778720950 @default.
• W2954184793 hasConceptScore W2954184793C2781059491 @default.
• W2954184793 hasConceptScore W2954184793C71924100 @default.
• W2954184793 hasConceptScore W2954184793C72563966 @default.
• W2954184793 hasIssue "11" @default.
• W2954184793 hasLocation W29541847931 @default.
• W2954184793 hasLocation W29541847932 @default.
• W2954184793 hasOpenAccess W2954184793 @default.
• W2954184793 hasPrimaryLocation W29541847931 @default.
• W2954184793 hasRelatedWork W1995727207 @default.
• W2954184793 hasRelatedWork W2090686119 @default.
• W2954184793 hasRelatedWork W2314052274 @default.
• W2954184793 hasRelatedWork W2317075994 @default.
• W2954184793 hasRelatedWork W2352829214 @default.
• W2954184793 hasRelatedWork W2361180466 @default.
• W2954184793 hasRelatedWork W2583372832 @default.
• W2954184793 hasRelatedWork W3045308555 @default.
• W2954184793 hasRelatedWork W2314697596 @default.
• W2954184793 hasRelatedWork W3089257917 @default.
• W2954184793 hasVolume "35" @default.
• W2954184793 isParatext "false" @default.
• W2954184793 isRetracted "false" @default.
• W2954184793 magId "2954184793" @default.
• W2954184793 workType "article" @default.